JETEMA (A216080) Stock Overview
A bio venture company, engages in the research and development of medicines and medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A216080 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
JETEMA, Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,900.00 |
| 52 Week High | ₩11,270.00 |
| 52 Week Low | ₩5,370.00 |
| Beta | 1 |
| 1 Month Change | 20.58% |
| 3 Month Change | 72.47% |
| 1 Year Change | 51.15% |
| 3 Year Change | -7.04% |
| 5 Year Change | 0.25% |
| Change since IPO | 128.90% |
Recent News & Updates
JETEMA, Co., Ltd.'s (KOSDAQ:216080) 30% Price Boost Is Out Of Tune With Revenues
Jan 15
These 4 Measures Indicate That JETEMA (KOSDAQ:216080) Is Using Debt Extensively
Nov 14Recent updates
JETEMA, Co., Ltd.'s (KOSDAQ:216080) 30% Price Boost Is Out Of Tune With Revenues
Jan 15These 4 Measures Indicate That JETEMA (KOSDAQ:216080) Is Using Debt Extensively
Nov 14Here's Why JETEMA (KOSDAQ:216080) Has A Meaningful Debt Burden
Jan 23JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News
Mar 23Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?
Feb 25JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt
Jan 21The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?
Dec 17
Shareholder Returns
| A216080 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.9% | 6.7% | 5.3% |
| 1Y | 51.1% | 58.6% | 109.3% |
Return vs Industry: A216080 underperformed the KR Pharmaceuticals industry which returned 59.8% over the past year.
Return vs Market: A216080 underperformed the KR Market which returned 105.7% over the past year.
Price Volatility
| A216080 volatility | |
|---|---|
| A216080 Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 13.2% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A216080's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A216080's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 265 | Jeong Sun Nam | www.jetema.com |
JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks.
JETEMA, Co., Ltd. Fundamentals Summary
| A216080 fundamental statistics | |
|---|---|
| Market cap | ₩356.47b |
| Earnings (TTM) | -₩4.36b |
| Revenue (TTM) | ₩75.55b |
Is A216080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A216080 income statement (TTM) | |
|---|---|
| Revenue | ₩75.55b |
| Cost of Revenue | ₩43.17b |
| Gross Profit | ₩32.38b |
| Other Expenses | ₩36.74b |
| Earnings | -₩4.36b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -121.20 |
| Gross Margin | 42.86% |
| Net Profit Margin | -5.78% |
| Debt/Equity Ratio | 193.4% |
How did A216080 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/21 19:28 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JETEMA, Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyun Jeong Son | Yuanta Securities Korea Co., Ltd. |